Accelerate Your Bacteroides vulgatus based Microbiome Therapeutic: CRO Service for Early-Stage Research
Background B. vulgatus and Diseases Case Study Services Products FAQs Resources
Probiotics have been proven to be useful in treating a variety of diseases. Bacteroides are the main candidates for the next generation of probiotics (NGPs), which have attracted extensive attention due to their relationship with host health and disease. Creative Biolabs offers well-established and innovative One-Stop-Shop live biotherapeutic product (LBP) development solutions. Our goal is to commercialize Bacteroides genus proprietary technology, including Bacteroides vulgatus (B. vulgatus). We have specialist technology to optimize each stage to ensure you get the results you want, achieving the highest level of efficiency throughout.
Introduction of B. vulgatus
B. vulgatus is a Bacteroides species that is common in the human colon and is associated with a healthy host gut. B. vulgatus is a Gram (-) obligate anaerobe most commonly found in human feces and has also been isolated from clinical specimens of patients, especially those with IBD. It can produce acetic, propanoic, and butyrate acids. One study showed that B. vulgatus accounts for more than 40% of the total gut microbiota of patients with Crohn's disease, but only 6% of the total gut microbiota of healthy humans. Therefore, it was also widely considered a representative of the Bacteroides genus associated with IBD. A new generation of probiotics, B. vulgatus, has also been found to prevent colitis, depending on the strain. One study reported that B. vulgatus mpk has potential probiotic properties with an ability to protect against E. coli mpk-induced colitis development in IL-2-/-mice. Interestingly, one study reported that B. vulgatus is highly resistant to inorganic arsenic because of its ability to express the arsenic resistance genes, suggesting that the probiotic effects of B. vulgatus also extend to the inhibition of heavy metal toxicity.
B. vulgatus and Diseases
-
Diminishes Colonic Microbiota Dysbiosis Ameliorating Lumbar Bone Loss in Ovariectomized Mice
The ovariectomized female C57/BL6 mice were gavaged with B. vulgatus to observe the differences in colon microbial composition, inflammatory signaling pathways, inflammatory cytokines, bone conversion markers, and lumbar microstructures compared with the control group. The results showed that B. vulgatus reduced microbiota dysregulation, down-regulated the colonic lipopolysaccharide /TLR-4/P-NF-κB pathway, and decreased the serum TNF-α level. Therefore, the results of this study suggest that B. vulgatus may be a probiotic for the treatment of postmenopausal lumbar osteoporosis.
-
The Protective Roles Against Dextran Sulfate Sodium- (DSS-) Induced Colitis
B. vulgatus is a representative species of the Bacteroides genus and is known to have a beneficial effect on human colon health. The strain-dependent role of B. vulgatus in alleviating intestinal inflammatory diseases has been demonstrated. The scientists selected four strains of B. vulgatus with widely differing genomes and assessed their role in mitigating colitis. The results showed that among the four B. vulgatus strains, only B. vulgatus 7K1 could significantly relieve five DSS-induced symptoms, including reduced body weight, a shortened colon, increased DAI scores, severe damage to the colon tissue, and increased intestinal permeability, but B. vulgatus 51K1 markedly deteriorated the symptoms of colitis in mice.
Fig.1 Schematic representation of antihyperlipidemia effect of B. vulgatus Bv46 on high-fat diet-fed rats.1
Case Study
|
Case 1: Innovative Probiotic Development with B. vulgatus
|
Creative Biolabs has embarked on an innovative study to explore the potential of B. vulgatus as a next-generation probiotic (NGP) targeting metabolic disorders and enhancing colon health. This focused research aimed at the development and quantitative preparation of a lyophilized powder form of B. vulgatus, achieving a target of 6×10^8 CFU/vial to facilitate effective administration in animal models. The rigorous process involved anaerobic cultivation, careful lyophilization to maintain high viability, and meticulous verification of the colony-forming unit (CFU) count, ensuring the probiotic's efficacy and safety for research purposes.
The results from the study were promising, with the final product containing 1.2×10^9 CFU across 25 vials, exceeding initial targets and demonstrating high activity levels suitable for further research. This was particularly significant as the high CFU concentration was pivotal in assessing the probiotic's therapeutic effects on mice. Utilizing a cryoprotectant blend of trehalose and skim milk as a placebo ensured the study's integrity, confirming the non-toxicity of the process to the bacterial strains and animal models, thereby validating the research methodology and findings.  Fig.2 B. vulgatus strain preparation. Creative Biolabs' dedication to quality and innovation is evident through this study, highlighting the potential of B. vulgatus lyophilized powder in promoting gut health and offering a promising avenue for the development of effective probiotic treatments. By surpassing CFU count expectations and employing rigorous preparation and verification methods, the research not only underscores the therapeutic benefits of B. vulgatus but also sets a benchmark for future live biotherapeutic product development, paving the way for significant advancements in probiotic applications.
|
Our Services for B. vulgatus Research
B. vulgatus Related Products
-
Customized strain culture supernatant. (e.g.: for animal research)
-
Customized strain lyophilized powder containing certain CFU. (e.g.: for animal research)
-
Strain products
We supply a variety of B. vulgatus strains of different preservation numbers as below. If you need other strains, please contact us.
Creative Biolabs is a leading international biotechnology company in the LBP industry, we believe in the transformative power of science and technology. We conducted extensive research on the potential use of B. vulgatus species. If you are interested in our B. vulgatus related services and products, please contact us for further discussion.
Frequently Asked Questions
What makes B. vulgatus a promising candidate for probiotic development?
B. vulgatus is promising for probiotic development due to its inherent stability in the gastrointestinal tract, ability to modulate the immune system, and its role in producing short-chain fatty acids which are vital for gut health. Moreover, it has a symbiotic relationship with human hosts, contributing to the suppression of harmful bacteria. Our B. vulgatus products are designed to harness these properties, offering a potent option for research in microbiome health and disease prevention.
Can B. vulgatus products be used in clinical settings?
Currently, our B. vulgatus products and discovery services are intended solely for research purposes and are not approved for diagnostic or therapeutic use in clinical settings. Researchers can utilize these products to explore the bacterium's role in human health and disease, develop new probiotic formulations, or study its interactions within the microbiome. We encourage scientific exploration to uncover the full potential of B. vulgatus, with the hope that future clinical applications may emerge from these research efforts.
How do your B. vulgatus discovery services support researchers?
Our B. vulgatus discovery services are tailored to support researchers in identifying, characterizing, and utilizing this bacterium for their specific study objectives. Services include strain isolation and identification, functional genomics, metabolic profiling, and custom probiotic formulation development. These services aim to accelerate research and development processes, enabling scientists to explore the therapeutic potential of B. vulgatus with state-of-the-art tools and expertise.
Resources
Reference
-
Xu, Mingchao, et al. "Bacteroides vulgatus ameliorates lipid metabolic disorders and modulates gut microbial composition in hyperlipidemic rats." Microbiology Spectrum 11.1 (2023): e02517-22. Distributed Under Open Access license CC BY 4.0, without modification.
For Research Use Only. Not intended for use in
food manufacturing or medical procedures (diagnostics or therapeutics). Do Not Use in Humans.
Related Services
